multinucl
cell
creat
result
spontan
vivo
cell
fusion
cf
describ
first
time
schwann
increas
knowledg
mechan
cf
process
defin
asexu
merg
entrap
content
two
membraneenclos
aqueou
compart
involv
mix
membran
content
produc
monoor
multinucl
cell
hybrid
vivo
cf
multistep
process
depend
interplay
mani
fulli
character
factor
includ
prime
prepar
cell
fusion
via
express
fusion
induc
protein
chemotaxi
migrat
cell
toward
via
chemokin
express
adhes
activ
cell
adhes
molecul
fusion
postfus
adjust
type
cell
form
result
vivo
ex
vivo
fusion
divid
depend
number
origin
nuclei
fuse
cell
well
type
cell
underw
fusion
fig
fusion
cell
gener
homotyp
fusion
cell
type
heterotyp
fusion
cell
differ
type
fashion
cell
origin
fusion
two
differ
type
known
hybrid
cell
follow
fusion
cell
may
contain
either
one
nucleu
synkaryon
creat
nuclear
fusion
two
nuclei
heterokaryon
cytoplasmat
fusion
fuse
cell
lifetim
nuclei
divis
synchron
cell
transform
heterokaryon
synkaryon
cell
knowledg
explain
molecular
mechan
vivo
spontan
cf
well
fuse
cell
properti
come
studi
cancer
cell
line
bone
marrow
transplant
first
vitro
spontan
cf
condit
mammalian
cell
establish
discoveri
spontan
fusion
pluripot
embryon
stem
cell
mous
bone
marrow
cell
brain
progenitor
cell
creat
interest
cf
process
could
appli
tissu
regener
cf
consid
one
forc
alter
cell
fate
modifi
phenotyp
function
multipl
vitro
studi
demonstr
hybrid
creat
result
fusion
present
mixedintermedi
phenotyp
gene
express
pattern
deriv
fusion
donor
migratori
activ
prolifer
capabl
cell
surfac
protein
express
drug
resist
work
pioneer
terada
ying
reveal
cell
creat
spontan
cf
could
express
phenotyp
characterist
undifferenti
cell
properti
type
cell
undergo
fusion
possibl
format
stabl
multinucl
heterokaryon
result
spontan
fusion
bone
marrow
deriv
cell
sever
type
fusion
friendli
cell
skelet
muscl
cardiac
muscl
liver
monocyt
mesenchym
stem
cell
hematopoiet
stem
cellsprogenitor
cell
macrophag
b
lymphocyt
intestin
cell
purkinj
neuron
confirm
multipl
vivo
studi
experi
fuse
cell
present
mix
phenotyp
also
overtook
function
injur
recipi
cell
help
facilit
process
tissu
regener
interest
applic
bone
marrow
deriv
cell
variou
medic
field
tissu
regener
transplant
increas
due
potenti
therapeut
effect
earli
vitro
cf
perform
describ
effect
virus
hemagglutin
viru
japan
hvj
murin
cell
cultur
current
three
major
cf
method
chemic
electr
viral
advantag
disadvantag
method
compil
present
tabl
new
method
cf
appli
differ
agent
cephalin
bispecif
nanoparticl
fusogen
cell
line
vfusion
investig
combin
differ
fusion
method
introduc
addit
modif
convent
techniqu
studi
improv
fusion
efficaci
either
increas
celltocel
contact
capabl
permeabil
area
select
proper
fusion
method
protocol
optim
depend
cell
type
cell
number
cultur
condit
monolay
vs
cell
suspens
sensit
unfavor
condit
equip
avail
efficaci
polykaryon
creation
control
factor
time
andor
fuse
agent
concentr
higher
number
polykaryon
also
gener
repeat
fusion
procedur
addit
applic
support
agent
dimethyl
sulfoxid
dmso
case
polyethylen
glycol
peg
mediat
fusion
confirm
effici
creat
higher
number
fuse
cell
use
peg
alon
peg
due
hydrophob
properti
decreas
distanc
cell
remov
water
thermodynam
unfavour
environ
caus
aggreg
dehydr
lead
asymmetri
lipid
membran
bilay
lead
format
singl
bilay
septum
point
close
apposit
two
cell
membran
facilit
format
pore
follow
septum
decay
fig
clinic
applic
ex
vivo
cf
limit
scarciti
knowledg
fusion
mechan
well
fuse
cell
function
safeti
howev
cf
potenti
becom
use
tool
armamentarium
highli
anticip
method
focus
organ
tissu
function
regener
current
cf
util
either
indirectli
product
monoclon
antibodi
directli
creat
cellular
therapeut
monoclon
antibodi
use
treat
varieti
diseas
condit
cancer
autoimmun
diseas
inflamm
transplant
reject
creation
immort
hybridoma
essenti
part
monoclon
antibodi
product
antibodi
directli
produc
mous
hybridoma
howev
basiliximab
chimer
antibodi
primarili
creat
mous
hybridoma
modifi
util
recombin
dna
technolog
replac
mous
immunogenet
compon
antibodi
human
protein
concept
direct
applic
ex
vivo
cf
creation
cellular
therapi
initi
observ
opposit
sex
hematopoiet
cell
transplant
abil
transplant
stem
cell
fuse
spontan
defect
cell
restor
function
origin
research
focus
creat
cellular
therapi
experiment
therapi
orient
toward
approach
fusion
differenti
cell
stem
cell
reprogram
special
cell
pluripot
state
via
cf
embryon
stem
cell
embryon
germ
cell
theori
ex
vivo
cf
could
appli
cellbas
genedeliveri
system
treat
genet
nongenet
diseas
muscular
dystrophi
tyrosinemia
hemophilia
diabet
type
approach
util
direct
applic
cf
found
cancer
immunotherapi
anticanc
vaccin
creat
ex
vivo
cf
dendrit
cell
dc
potent
antigen
present
cell
carcinoma
cell
among
promis
strategi
dedic
introduc
cancer
specif
antigen
dc
aim
approach
enhanc
immun
system
respons
cancer
cell
fusion
dc
tumor
cell
elimin
limit
low
number
known
tumorassoci
antigen
avail
hla
molecul
hybrid
cell
contain
unidentifi
molecul
express
combin
mhc
class
ii
molecul
presenc
costimulatori
signal
may
effect
altern
patient
suffer
rare
form
cancer
result
cancer
immunotherapi
use
anticanc
vaccin
vitro
well
mous
model
show
potent
antitumor
respons
multipl
tumorassoci
antigen
current
immunotherapi
evalu
treatment
melanoma
breast
cancer
patient
phase
ii
clinic
trial
infus
bone
marrowderiv
cell
presenc
chimer
peripher
blood
follow
migrat
donorderiv
cell
lymphoid
organ
associ
prolong
surviv
transplant
even
toler
induct
bond
et
al
report
cocultur
spontan
fusion
bone
marrow
cell
deriv
two
differ
mice
strain
occur
vivo
studi
confirm
result
follow
allogen
syngen
transplant
shown
fuse
cell
surfac
express
donor
recipi
mhc
antigen
siemionow
group
also
perform
experi
cf
bone
marrow
deriv
cell
result
preliminari
studi
line
result
bond
et
al
show
possibl
creat
vivo
donorrecipi
fuse
cell
facilit
face
allograft
surviv
articl
press
short
immunomodulatori
protocol
monoclon
antibodi
cyclosporin
use
facilit
engraft
spontan
creat
donorrecipi
chimer
cell
drcc
success
establish
protocol
creat
vivo
drcc
either
via
mechan
trogocytosi
spontan
cf
open
mani
possibl
use
bone
marrow
deriv
cell
tool
develop
novel
therapeut
product
although
research
drcc
necessari
order
fulli
understand
underli
mechan
creation
action
vivo
creation
toleranceinduct
cell
could
breakthrough
modal
solid
organ
cta
transplant
sever
disadvantag
creat
drcc
vivo
clinic
scenario
describ
previou
chapter
challeng
issu
clinic
execut
primari
chimera
creation
protocol
critic
time
frame
follow
bone
marrow
infus
requir
develop
chimer
protolerogen
environ
transplant
recipi
pretreat
transplant
recipi
order
creat
vivo
drcc
possibl
live
organ
donor
overcom
hindranc
move
forward
clinic
applic
model
siemionow
group
adopt
new
approach
creat
drcc
via
ex
vivo
cf
drcc
therapi
creat
fusion
donor
recipi
bone
marrow
deriv
cell
polyethylen
glycol
peg
techniqu
briefli
bone
marrow
cell
harvest
tibia
femur
bone
two
fulli
mhc
mismatch
aci
lewi
rat
use
flush
techniqu
next
erythrocyt
remov
white
blood
cell
donor
separ
stain
redorang
green
cell
membran
fluoresc
dye
fluoresc
stain
cell
appli
order
detect
separ
doubl
stain
green
redorang
drcc
creat
fusion
use
fluoresc
activ
cell
sort
fig
peg
mediat
ex
vivo
fusion
protocol
feasibl
perform
surgic
unit
provid
higher
number
drcc
compar
vivo
protocol
techniqu
requir
cell
similar
diamet
specif
proport
electrofus
siemionow
team
success
confirm
feasibl
fusion
protocol
creation
drcc
assess
drcc
confirm
presenc
mhc
class
deriv
donor
surfac
chimer
cell
well
presenc
aci
lewisspecif
genom
sequenc
phenotyp
evalu
show
chimer
cell
posit
addit
mix
lymphocyt
reaction
mlr
assay
show
immunolog
unrespons
chimer
cell
coloni
form
unit
assay
reveal
chimer
cell
abl
creat
type
compar
number
coloni
untreat
bone
marrow
cell
drcc
test
vivo
support
therapi
allogen
vascular
skin
allograft
siemionow
laboratori
seven
day
immunosuppress
protocol
monoclon
antibodi
cyclosporin
mgkgday
result
studi
show
increas
surviv
allograft
confirm
protolerogen
properti
drcc
prolong
surviv
fulli
mhc
mismatch
allograft
associ
presenc
donorderiv
cell
peripher
blood
lymphoid
organ
recipi
rat
one
potenti
drcc
mechan
action
might
similar
one
observ
chow
et
al
cell
express
recipi
mhc
abl
avoid
detect
recipi
immun
respons
anoth
possibl
mechan
migrat
drcc
lymphoid
organ
thymu
cell
affect
select
donorreact
cell
caus
induct
chimer
accept
allograft
donor
specif
transfer
toler
via
drcc
new
strategi
gener
custom
made
cellular
therapeut
high
specif
individu
patient
build
promis
result
vivo
studi
siemionow
group
progress
test
feasibl
ex
vivo
creat
chimer
cell
protocol
use
human
cord
blood
cell
proof
concept
preliminari
experi
confirm
feasibl
siemionow
group
protocol
creation
chimer
cell
analysi
drcc
confirm
fusion
produc
viabl
cell
present
surfac
hla
class
ii
characterist
donor
prolifer
capabl
compar
untreat
cord
blood
control
futur
siemionow
group
focu
creation
drcc
human
bone
marrow
bone
marrow
primari
sourc
cell
ex
vivo
cf
therapeut
purpos
support
therapi
case
bone
marrow
avail
ie
recipi
suffer
sever
bone
marrow
defici
due
gamma
irradi
deceas
organ
donor
altern
use
match
cord
blood
cell
possibl
interchang
applic
either
bone
marrow
cord
blood
cell
provid
assur
suffici
number
chimer
cell
obtain
time
fig
siemionow
group
toler
induc
protocol
direct
intraoss
transplant
drcc
appli
patient
requir
either
solid
organ
vca
transplant
support
therapi
order
facilit
develop
tolerantinduc
microenviron
transplant
addit
human
chimer
cell
therapi
may
clinic
applic
treatment
diseas
base
bone
marrow
transplant
chimer
cell
therapi
improv
engraft
donororigin
cell
facilit
induct
donorspecif
immun
nonrespons
solid
organ
vca
transplant
applic
establish
protocol
seven
day
immunosuppress
improv
develop
donorspecif
mix
chimer
confirm
murin
model
siemionow
laboratori
innov
support
therapi
repres
breakthrough
modal
field
reconstruct
transplant
